RESOURCE LIBRARY

Advancing medicine through scientific ingenuity

RESOURCE LIBRARY

Advancing medicine science through scientific ingenuity

At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.

Filter by

CLEAR
Wednesday, September 3, 2025
SOHO 2025 Annual Meeting
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia
Wednesday, September 3, 2025
SOHO 2025 Annual Meeting
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study
Wednesday, September 3, 2025
SOHO 2025 Annual Meeting
A Phase 1 Trial of Zelebrudomide (NX-2127), a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients with Relapsed/Refractory B-cell Malignancies
Tuesday, July 22, 2025
Bay Area Biotech Day
Machine Learning Frameworks for Predictive PK/PD Modeling of Degraders from Fragmented Multi-Source Data
Tuesday, July 22, 2025
Bay Area Biotech Day
Rewriting Established Drug Design Rules with a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader
Tuesday, July 22, 2025
Bay Area Biotech Day
From Incremental to Exponential: Integrating AI and DEL to Enable Discovery Across the Proteome
Tuesday, July 22, 2025
Bay Area Biotech Day
Leveraging Degrader Antibody Conjugates and Novel Ligases to Achieve Superior Delivery, Efficacy and Selectivity
Saturday, June 21, 2025
ICML
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia
Saturday, June 21, 2025
ICML
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study
Thursday, June 12, 2025
EHA
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study